For paclitaxel, another anticancer agent used in ovarian cancer chemotherapy, Han et al. reported that ANXA4 expression was induced in a lung cancer cell line by paclitaxel treatment in vitro, and overexpression of ANXA4 in 293T cells conferred paclitaxel resistance [22]. Here, ANXA4 is linked to ovarian carcinoma.